Neuropeptide content of lungs from asthmatic and nonasthmatic patients.
Neuropeptide content of lungs from asthmatic and nonasthmatic patients.
复制标题
哮喘和非哮喘患者肺部的神经肽含量。
DOI：
10.1164/ajrccm.151.2.7531100
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Drazen,JM
中科院分区：
文献类型：
--
作者：
Lilly,CM;Bai,TR;Shore,SA;Hall,AE;Drazen,JM
用HPLC纯化的哮喘患者和非哮喘患者的组织提取物测定气管和肺实质SP-LI（P物质样免疫反应性）和VIP-LI（血管活性肠肽样免疫反应性）含量。我们检测到哮喘患者气管组织中SP-LI显著低于非哮喘患者，而两组间实质SP-LI含量无显著差异。这一发现并不支持哮喘肺中含有过量SP的概念。事实上，哮喘患者气管组织中SP-LI含量较低可能反映了SP释放增加，随后降解。我们在两组中检测到气管中的VIP-LI含量高于实质组织，但在哮喘和非哮喘患者的气管或实质组织中未检测到VIP-LI含量有显着差异。这些发现表明哮喘和非哮喘肺含有相似水平的VIP。
Tracheal and lung parenchymal SP-LI (substance P-like immunoreactivity) and VIP-LI (vasoactive intestinal peptide-like immunoreactivity) content was measured in HPLC-purified tissue extracts from patients with and without asthma. We detected significantly less SP-LI in tracheal tissue from asthmatic than from nonasthmatic patients, whereas parenchymal SP-LI content was not significantly different between these groups. This finding does not support the concept that asthmatic lungs contain excessive amounts of SP. Indeed, lower SP-LI content of tracheal tissues from asthmatic patients may reflect augmented SP release followed by degradation. We detected greater quantities of VIP-LI in tracheal than in parenchymal tissue in both groups, but did not detect significant differences in VIP-LI content in tracheal or parenchymal tissues from asthmatic and nonasthmatic patients. These findings indicate that asthmatic and nonasthmatic lungs contain similar levels of VIP.
肺部炎症发病机制中的神经肽。
DOI：
--
发表时间：
1988
期刊：
American Review of Respiratory Disease
影响因子：
--
作者：
T. Casale;W. Busse;M. Kaliner;S. Said;P. Barnes
通讯作者：
P. Barnes
哮喘患者和非哮喘患者气道中的 P 物质免疫反应神经。
影响因子：
24.3
作者：
S. Ollerenshaw;D. Jarvis;C. Sullivan;A. Woolcock
通讯作者：
A. Woolcock
神经激肽 A 是一种有效的支气管收缩剂。
DOI：
10.1164/ajrccm/136.3.718
发表时间：
1987
期刊：
The American review of respiratory disease
影响因子：
--
作者：
Y. Uchida;A. Nomura;M. Ohtsuka;S. Hasegawa;K. Goto;S. Kimura;Y. Sugita;Y. Uchiyama
通讯作者：
Y. Uchiyama